ACTRN12620001356954终止2 期
A Phase II, multicentre, double-blind, randomised, placebo-controlled trial to demonstrate the efficacy and safety of BP101 in patients with hypoactive sexual desire disorder.
OVB (Australia) Pty Ltd0 个研究点目标入组 453 人开始时间: 2020年12月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 453
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 21 Years 至 50 Years（—）
- 性别
- Female
入选标准
- •1) Women aged 21-50 years (inclusive).
- •2) Pre-menopausal with regular menstrual cycles. Pre-menopausal participants that are currently on menstrual cycle-altering hormonal contraception can be included.
- •3) Have acquired, generalised hypoactive sexual desire disorder for at least 24 weeks duration prior to Screening.
- •4) Female Sexual Function Index Desire domain score of less than or equal to 5 at Screening.
- •5) Female Sexual Distress Scale-Desire/Arousal/Orgasm total score >18 at Screening.
- •6) In a stable relationship with the same sexually active partner for greater than or equal to 1 year. The partner must be physically available for greater than or equal to 50% of time throughout the study and must not have any sexual dysfunctions.
- •7) Consent to attempt to have sexual activity at least twice per month.
排除标准
- •1) Diagnosed with other sexual dysfunction or mental disorder which may impact sexual function.
- •2) Beck Depression Inventory score of greater than or equal to 21 during Screening.
- •3) Have been receiving non-pharmaceutical psychotherapeutic treatment for sexual problems within 12 weeks prior to Screening or planning a psychotherapeutic course during the study.
- •4) If in the Investigator’s opinion the participant has obvious life stress conditions (death of someone close, legal or financial difficulties), personal problems in relationships, or relationship problems with their partner that are not sexual discord arising from the problems of HSDD, that may have a significant impact on sexual activity during the study.
- •5) History of chronic diseases of the nasal cavity and nasopharynx or rhinitis and/or other acute inflammatory diseases of the nasal cavity or nasopharynx within four weeks prior to randomisation.
- •6) History of neurological disorder that would affect cognition.
- •7) Body mass index (BMI) of greater than or equal to 38.0 kg/m2.
- •8) History of diagnosed polycystic ovarian syndrome.
- •9) Cancer in the past, other than basal cell carcinoma or squamous cell carcinoma, that has not fully resolved with adequate therapy greater than or equal to five years prior to randomisation.
- •10) History of inflammatory diseases of pelvic organs, infections of the genitourinary system, cervicitis, interstitial cystitis, vulvodynia or severe atrophy of the vaginal epithelium, or any other chronic gynaecological pathology within four weeks prior to Screening, or at any time in the past if, in the Investigator’s opinion, it may interfere with normal sexual activity.
- •11) History of surgical interventions (other than cosmetic surgeries) on reproductive organs which result in dyspareunia, impede sexual activity, require maintenance sex hormone therapy, and/or lead to a decrease in sensitivity during sexual events.
- •12) Current clinically significant or unstable comorbidity or pathology which, in the Investigator’s opinion, may interfere with normal sexual activity, precludes the inclusion of the participant for safety purposes, or may affect the outcomes of the study.
- •13) Women who are pregnant, within the first 12 months post-partum, or women who are breastfeeding.
研究者
相似试验
进行中（未招募）
1 期
Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’s disease recurrencePost-operative endoscopic Crohn’s disease recurrenceMedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856EUCTR2017-002258-36-DEALFASIGMA S.P.A.180
进行中（未招募）
1 期
Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’sdisease recurrencePost-operative endoscopic Crohn’s disease recurrenceMedDRA version: 20.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000016693EUCTR2017-002258-36-ESALFASIGMA S.P.A.180
已完成
2 期
A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Crohn*s disease recurrence (STOP-Postoperative Endoscopic Recurrence Study)Chronic intestinal inflammationMorbus Crohn10017969NL-OMON46817Alfasigma S.p.A.24
进行中（未招募）
1 期
Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’s disease recurrencePost-operative endoscopic Crohn’s disease recurrenceMedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856EUCTR2017-002258-36-BEALFASIGMA S.P.A.180
进行中（未招募）
1 期
Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’sdisease recurrenceEUCTR2017-002258-36-NLALFASIGMA S.P.A.180